The research published today looked at treatment records in 615 U.S. hospitals from 2000 to 2008 and examined 64 studies of NovoSeven to assess outcomes and side effects. Veronica Yank and Aaron Logan of Stanford University School of Medicine near Palo Alto, California, led the analysis.
Along with being ineffective in those patients, the drug also costs $10,000 per dose, said the study. In an editorial accompanying the studies, Jerry Avorn, a physician at Harvard Medical School in Boston, said investigators should look into whether Novo made any effort to market the drug for the unapproved uses.
via bloomberg.com
No comments:
Post a Comment